21 completed, 6 unknown, 4 terminated, 3 not yet recruiting. 35 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 35 | Completed 21, Unknown 6, Terminated 4, Not yet recruiting 3, Withdrawn 1 |
Follow Aprepitant: new trials by email Literature Review of Aprepitant trials Research Report on Aprepitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aprepitant to Improve Same Day Discharge for TKA Aprepitant Injection, Ondansetron (Zofran), Dexamethasone - PONV | Phase 4 | Not yet recruiting | Endeavor Health | 350 | 2026-07-01 | 2026-06-10 |
| Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery Aprepitant, Placebo - Otologic Disease | Phase 4 | Not yet recruiting | Sir Mortimer B. Davis - Jewish General Hospital | 100 | 2026-06-01 | 2026-01-28 |
| Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer Ondansetron 8mg, Aprepitant 125 mg - Thyroid Cancer | Phase 4 | Completed | The First Affiliated Hospital of Zhengzhou University | 600 | 2024-07-01 | 2025-01-22 |
| Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer Aprepitant, Palonosetron, Fosaprepitant - Breast Cancer, Chemotherapy-induced Nausea and Vomiting | Phase 4 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 1028 | 2023-07-01 | 2023-05-03 |
| The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting Aprepitant, Placebo - Obesity, Nausea and Vomiting, Postoperative | Phase 4 | Unknown | Hospital General Tlahuac | 400 | 2022-12-01 | 2023-03-16 |
| Postoperative Nausea and Vomiting in Laparoscopic Abdominal Surgery Aprepitant, Granisetron - Postoperative Nausea, Vomiting | Phase 4 | Unknown | Baskent University | 60 | 2022-11-24 | 2022-11-30 |
| Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery. Aprepitant 80 mg, Placebo - Postoperative Nausea and Vomiting, Bariatric Surgery | Phase 4 | Terminated | Insel Gruppe AG, University Hospital Bern | 71 | 2022-03-17 | 2025-02-27 |
| Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 LCZ 696, Placebo, Para-aminohippurate - Heart Failure | Phase 4 | Completed | Yale University | 46 | 2021-05-27 | 2026-10-27 |
| Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045) Fosaprepitant Dimeglumine, 5-HT3 antagonist, Dexamethasone - Chemotherapy-induced Nausea and Vomiting | Phase 4 | Completed | Merck Sharp & Dohme LLC | 103 | 2019-09-09 | 2025-01-16 |
| Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting Aprepitant and Dexamethasone, Mirtazapine and Dexamethasone, Dexamethasone - Nausea and Vomiting, Postoperative | Phase 4 | Completed | Ain Shams University | 90 | 2019-07-15 | 2020-01-03 |
| Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy Aprepitant 80 mg Oral Capsule, scopolamine transdermal, Total intravenous anesthesia - Post-operative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy | Phase 4 | Completed | Stony Brook University | 83 | 2017-08-28 | 2024-02-14 |
| A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation Tropisetron, Dexamethasone, Aprepitant - Vomiting | Phase 4 | Unknown | Jun Zhu | 130 | 2015-10-01 | 2016-12-30 |
| Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone ramosetron, aprepitant, dexamethasone, palonosetron, aprepitant, dexamethasone - Cancer, Tumors | Phase 4 | Completed | Kangdong Sacred Heart Hospital | 292 | 2015-08-19 | 2018-05-11 |
| Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Aprepitant - Leukemia, Lymphoma | Phase 4 | Unknown | Sun Yat-sen University | 85 | 2015-04-01 | 2015-01-27 |
| Neurokinin Receptor Antagonist Associated to Ondansetron in PONV Aprepitant - Postoperative Nausea and Vomiting | Phase 4 | Completed | Instituto do Cancer do Estado de São Paulo | 90 | 2015-02-01 | 2015-08-25 |
| Palonosetron Associated to Aprepitant in Prophylaxis of PONV Aprepitant, Placebo, Dexamethasone - Postoperative Nausea and Vomiting | Phase 4 | Unknown | Instituto do Cancer do Estado de São Paulo | 90 | 2014-10-01 | 2015-05-01 |
| A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) Aprepitant, Aprepitant Placebo, Ondansetron - Nausea, Vomiting | Phase 4 | Completed | Merck Sharp & Dohme LLC | 494 | 2012-12-12 | 2018-09-25 |
| The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting Aprepitant, placebo - Postoperative Nausea and Vomiting | Phase 4 | Completed | Yonsei University | 125 | 2012-06-01 | 2013-07-11 |
| Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome Aprepitant, Placebo - Sezary Syndrome, Pruritus | Phase 4 | Terminated | Vanderbilt University Medical Center | 7 | 2012-02-01 | 2017-05-10 |
| Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients. Dexamethasone, Ondansetron, Aprepitant, Arm A: Standard Anti-emetic regimen - Emesis | Phase 4 | Unknown | Ottawa Hospital Research Institute | 323 | 2011-09-01 | 2017-01-30 |
Showing 20 of 35. Sign in to see all of them.
Vomiting (17) · Postoperative Nausea and Vomiting (14) · Nausea (12) · Breast Neoplasms (3) · Lymphoma (3) · Neoplasms (3) · Leukemia (2) · Ear Diseases (1) · Heart Failure (1) · Hematologic Neoplasms (1) · Obesity (1) · Ovarian Neoplasms (1) · Post-Dural Puncture Headache (1) · Pruritus (1) · Sezary Syndrome (1)
Merck Sharp & Dohme LLC (4) · Instituto do Cancer do Estado de São Paulo (2) · Radboud University Medical Center (2) · Ain Shams University (1) · Baskent University (1) · Duke University (1) · Endeavor Health (1) · Gynecologic Oncology Associates (1) · Hospital General Tlahuac (1) · Insel Gruppe AG, University Hospital Bern (1) · Jun Zhu (1) · Kangdong Sacred Heart Hospital (1) · Loyola University (1) · Mayo Clinic (1) · Ottawa Hospital Research Institute (1)
United States (11) · China (3) · Brazil (2) · Canada (2) · Netherlands (2) · South Korea (2) · Spain (2) · Turkey (Türkiye) (2) · Egypt (1) · France (1) · Greece (1) · Hungary (1) · Lithuania (1) · Mexico (1) · Peru (1)
David M. Burger, PharmD PhD (2) · Ashraf S Habib, MBBCH, FRCA (1) · Christian M Beilstein, MD (1) · Detao Yin, M.D. (1) · Javier Magrina, MD (1) · Jin-Hyoung Kang, Ph.D (1) · John P Micha, MD (1) · Jun Zhu, MD (1) · Jung Hye Kwon, PhD (1) · Konstantinos Spaniolas, MD (1) · Liang Wang, DOCTOR (1)
PMID 20871394, PMID 21081776, PMID 25165427, PMID 25220550, PMID 26562292, PMID 26694939, PMID 26994459, PMID 27826874, PMID 30140912, PMID 32471973, PMID 32632956, PMID 32901672, PMID 33528788, PMID 35535050, PMID 38429485, PMID 39655741
2008 (1), 2018 (1)